Who owns Guardant health?
Number of employees : 864 people….2020.
| Name | Title |
|---|---|
| Helmy Eltoukhy | Chairman & Co-Chief Executive Officer |
| AmirAli H. Talasaz | President, Co-Chief Executive Officer & Director |
When did Guardant health go public?
Oct. 4, 2018
On the market open on Oct. 4, 2018, Guardant Health’s shares traded at a 46% premium to the IPO price.
How accurate is Guardant 360?
The secured digital sequencing method of Guardant360® is 1000x more accurate than standard sequencing methods and results in a 99.9999% specificity.
How much does Guardant360 cost?
To learn more, contact Guardant Health client services. For patients without insurance, the cash pay rate for Guardant360 CDx is $5,000 effective the first day of commercial launch September 28, 2020.
Is Guardant health a good company?
Guardant is a great company, however, huge employee turnover rates. My department has had so many new people within the last year, and some of my fellow employees got laid off which makes it scary.
What kind of company is Guardant health?
biotechnology company
Guardant Health, Inc. operates as a biotechnology company. The Company provides sequencing and cell diagnostics services for the cancer patients. Guardant Health serves patients worldwide.
Is Guardant health a biotech company?
Guardant Health, Inc. operates as a biotechnology company. The Company provides sequencing and cell diagnostics services for the cancer patients.
When was Guardant founded?
2012
Guardant Health is a biotechnology company developing precision oncology treatments that is headquartered in Redwood City, California and was founded in 2012 by AmirAli Talasaz and Helmy Eltoukhy.
How much does a liquid biopsy cost?
At $5,800, the test itself costs the same amount as Roche’s equivalent tissue test, FoundationOne CDx. But prioritising a liquid assay would save money as well as being quicker and easier, since a blood draw is much cheaper than a surgical procedure.
Is a liquid biopsy invasive?
A liquid biopsy is a simple and non-invasive alternative to surgical biopsies which enables doctors to discover a range of information about a tumour through a simple blood sample.
Is Guardant 360 FDA approved?
The FDA has approved Guardant360, a liquid biopsy companion diagnostic for tumor mutation profiling or comprehensive genomic profiling to identify patients with locally advanced or metastatic non-small cell lung cancer who have a KRAS G12C mutation and may benefit from sotorasib.
Does Medicare pay for liquid biopsy?
Both tests are covered under Medicare. But for private insurance companies, coverage of liquid biopsy tests has varied by the company and the type of test used. In many cases, the cost is only covered if the test was used to check for genetic changes that have companion diagnostic approvals.
What is guardant 360 testing?
The “Guardant 360” test is designed to help patients avoid risky and expensive biopsies. The genomic test helps pair patients who have advanced cancer with targeted therapies, as well as with emerging drugs in clinical trials.
What is guardant testing?
Guardant makes a “liquid biopsy” test, called Guardant360, that uses blood samples from cancer patients and sequences the genetic information in that blood to figure out what might be the best way to treat a certain tumor.
Whether liquid biopsies will be cost-effective is unknown. Guardant’s test costs $5,400; some insurers cover it for certain types of patients. Gene profiling from a tissue biopsy costs about the same. The promise of liquid biopsies is that they can be done periodically to monitor care, but more tests means more cost.
What is a liquid biopsy cancer test?
A liquid biopsy is a test that is used to find evidence of cancer in a blood draw.